Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β 2 -Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid
Restricted accessResearch articleFirst published online November, 2017
Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β 2 -Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid
Background: The recent approval of several fixed-dose combination long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of dual bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD). Understanding the comparative safety of this combination is important for informing treatment decisions. Objective: To compare the risk of cardiovascular and cerebrovascular (CCV) events associated with LABA/LAMA compared with a combination of LABA and inhaled corticosteroid (ICS). Methods: This was a retrospective, observational cohort study using health insurance claims data to identify COPD patients initiating LABA/LAMA or LABA/ICS. CCV outcomes included hospitalizations with a primary diagnosis for acute coronary syndrome, heart failure, cardiac dysrhythmia, stroke, or transient ischemic attack. Patients were followed until they experienced an event, discontinued treatment, initiated medication from the opposite cohort, or lost enrollment. Patients were matched 1:4 on propensity scores, and time to event was compared using Cox proportional hazards models. Results: After matching, there were 3842 patients in the LABA/LAMA cohort and 15 225 in the LABA/ICS cohort. Cardiovascular events in the LABA/LAMA cohort were lower than in the LABA/ICS: hazard ratio (HR) = 0.794; 95% CI = 0.623-0.997. No significant difference in the risk of cerebrovascular events (HR = 1.166; 95% CI = 0.653-1.959) was observed. Conclusions: Despite concerns about the CCV effects of LAMA and LABA monotherapy, the LABA/LAMA combination had similar or lower risk of these events in comparison to LABA/ICS. Further studies are recommended to confirm these findings.
MalerbaMMorjariaJBRadaeliA.Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD: role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014;9:687-695.
Global Strategy for Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/. Accessed June 24, 2017.
4.
KarnerCCatesCJ.Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(4):CD008989.
SalpeterSRBuckleyNSSalpeterEE.Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med. 2006;21:1011-1019.
9.
AnthonisenNRConnettJEEnrightPLManfredaJ; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166:333-339.
10.
LeeTAPickardASAuDHBartleBWeissKB.Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149:380-390.
11.
SinghSLokeYKEnrightPLFurbergCD.Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215.
12.
TashkinDPCelliBSennS. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
13.
WiseRAAnzuetoACottonD; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369:1491-1501.
14.
CelliBDecramerMKestenSLiuDMehraSTashkinDP; UPLIFT Study Investigators. Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2009;180:948-955.
15.
ChenWThomasJSadatsafaviMFitzGeraldJM.Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3:631-639.
16.
MaclayJDMacNeeW.Cardiovascular disease in COPD. Chest. 2013;143:798-807.
17.
CalverleyPMAndersonJACelliB; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65:719-725.
18.
Department of Health and Human Services. Code of Federal Regulations Title 45 Public Welfare: Part 46 Protection of Human Subjects. Washington, DC: Department of Health and Human Services; 2009.
RosenbaumPRRubinDB.Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Statistician. 1985;39:33-38.
23.
ArbogastPGRayWA.Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res. 2009;18:67-80.
24.
WedzichaJADahlRBuhlR. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med. 2014;108:1498-1507.
25.
NaccarelliGFinkleJChopraBBrooksJHarrisSChurchA.Cardiovascular safety of umeclidinium/vilanterol in COPD: results from eight randomized clinical trials. Am J Respir Crit Care Med. 2014;189:A3766.
26.
BuhlRMaltaisFAbrahamsR. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45:969-979.
27.
VogelmeierCFBatemanEDPallanteJ. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51-60.
28.
WedzichaJABanerjiDChapmanKR. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374:2222-2234.
29.
SampJCJooMJSchumockGTCalipGSPickardASLeeTA.Comparative effectiveness of long-acting beta2-agonist combined with a long-acting muscarinic antagonist or inhaled corticosteroid in chronic obstructive pulmonary disease. Pharmacotherapy. 2017;37:447-455.
30.
OgaleSSLeeTAAuDHBoudreauDMSullivanSD.Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137:13-19.
31.
HennessySLeonardCEFreemanCP. Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf. 2010;19:555-562.
